X
Pharma Advancement
  • Home
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    development of new antibiotics

    EMA guidance supports development of new antibiotics

    Thermo Fisher Scientific Announces Collaboration with Northeastern University to Advance Biopharmaceutical Characterization and Monitoring Workflows

    Commercial Success In New Biopharmaceutical Innovation Era

    Proteros and AstraZeneca Boost Collaboration Agreement

    Conver to wp

    AbbVie and Cugene Join Forces Concerning Autoimmune Disorders and Cancer

    Drug Imagent For Therapeutic Platform

    Japan Pharma Lobby Says-Price Scheme Is Causing Drug Lag

    Charles River and Valence Discovery Announce Strategic Partnership to Provide Clients with AI-Enabled Drug Design Capabilities

    Charles River and Valo Launch Logica, an Integrated AI-Powered Drug Discovery Solution to Rapidly Deliver Optimized Preclinical Assets

    AstraZeneca announces phase IV ASCENT trial of Tudorza Pressair in patients with COPD meets primary efficacy endpoint

    AstraZeneca announces plans for new strategic R&D centre and Alexion headquarters in Cambridge, Massachusetts

    Lynparza approved in the EU for BRCA-mutated metastatic pancreatic cancer

    Major Success Factors For Clinical Development Organizations

    ArisGlobal Expands LifeSphere Clinical Portfolio with Landmark Customer Wins in APAC & Middle East

    ArisGlobal Expands LifeSphere Clinical Portfolio with Landmark Customer Wins in APAC & Middle East

  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us
No Result
View All Result
  • Home
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    development of new antibiotics

    EMA guidance supports development of new antibiotics

    Thermo Fisher Scientific Announces Collaboration with Northeastern University to Advance Biopharmaceutical Characterization and Monitoring Workflows

    Commercial Success In New Biopharmaceutical Innovation Era

    Proteros and AstraZeneca Boost Collaboration Agreement

    Conver to wp

    AbbVie and Cugene Join Forces Concerning Autoimmune Disorders and Cancer

    Drug Imagent For Therapeutic Platform

    Japan Pharma Lobby Says-Price Scheme Is Causing Drug Lag

    Charles River and Valence Discovery Announce Strategic Partnership to Provide Clients with AI-Enabled Drug Design Capabilities

    Charles River and Valo Launch Logica, an Integrated AI-Powered Drug Discovery Solution to Rapidly Deliver Optimized Preclinical Assets

    AstraZeneca announces phase IV ASCENT trial of Tudorza Pressair in patients with COPD meets primary efficacy endpoint

    AstraZeneca announces plans for new strategic R&D centre and Alexion headquarters in Cambridge, Massachusetts

    Lynparza approved in the EU for BRCA-mutated metastatic pancreatic cancer

    Major Success Factors For Clinical Development Organizations

    ArisGlobal Expands LifeSphere Clinical Portfolio with Landmark Customer Wins in APAC & Middle East

    ArisGlobal Expands LifeSphere Clinical Portfolio with Landmark Customer Wins in APAC & Middle East

  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us
No Result
View All Result
Pharma Advancement
No Result
View All Result
Home Drug Development Research & Development

Vantage Cancer Care Network Collaborates with Alliance Cancer Specialists, PC, to Expand the Delivery of High-Quality Cancer Care across Philadelphia

Content Team by Content Team
16th January 2018
in Research & Development
Vantage Cancer Care Network Collaborates with Alliance Cancer Specialists, PC, to Expand the Delivery of High-Quality Cancer Care across Philadelphia

Vantage Cancer Care Network (VCCN), a leader in value-based integrated cancer care, announced an agreement with Alliance Cancer Specialists, PC, to expand the delivery of high-quality oncology care across the Philadelphia region. Under the agreement, 21 oncologists across 11 locations are joining VCCN and will collaborate on providing seamless and efficient oncology care.

“We are privileged to join the Vantage Cancer Care Network in order to more closely align with like-minded physicians striving to improve quality and outcomes while lowering the overall cost of cancer care,” said Ann Marie Edwards, chief executive officer, Alliance Cancer Specialists, PC.

Physicians will benefit from VCCN’s expertise on value-based agreements, analytics tools, and process-improvement insights to help them achieve savings and quality outcomes in a value-based environment. As a result of this collaboration, VCCN will have a network of nearly 100 oncologists across 28 locations in the Philadelphia region.

“VCCN is pleased to join forces with Alliance Cancer Specialists,” said John Iacuone, MD, president & chief clinical officer, Vantage Cancer Care Network. “Alliance and VCCN are committed to working together so citizens of Philadelphia have access to high-quality cancer care and a superior patient experience, all while providing value to our health plan colleagues.”

About Alliance Cancer Specialists, PC
At Alliance, we’ve aligned the largest community-based team of cancer experts in Southeastern Pennsylvania. We offer quality cancer care that provides every advantage to help control and cure the disease.

Our approach guarantees new patients will be seen within 48 hours by one of our cancer experts. After evaluation, our team will provide a well-coordinated, tailored plan with diagnostic testing, the most powerful and precise treatment options, and compassionate care. With our combined strength and broad expertise, we provide the highest level of service to our patients and referring physicians in the Delaware Valley. To learn more visit www.alliancecancer.com

About Vantage Cancer Care Network
Vantage Cancer Care Network (VCCN) was founded to optimize cancer outcomes in a value-based, patient-centered care environment by developing cancer care networks to deliver appropriate, personalized and cost-effective care. VCCN is providing solutions to meet the growing needs of the oncology marketplace such as Carelytics™, a data management and reporting analytics tool. VCCN works with various oncology specialties to manage patient care through evidence-based treatment modalities. VCCN is supported by McKesson Specialty Health, a division of McKesson Corporation empowering the community patient care delivery system by helping community practices advance the science, technology and quality of care.

PR Contact
Claire Crye, VCCN
Claire.Crye@McKesson.com

Tina Bellanca, Alliance Cancer Specialists, PC
TBellanca@lmiadvertising.com

Previous Post

START & Sarah Cannon Partner to Advance Therapies for Patients with Cancer

Next Post

iMedrix Announces General Availability of KardioScreen, a CE certified, Connected ECG Device for Universal Use

Related Posts

Thermo Fisher Scientific Announces Collaboration with Northeastern University to Advance Biopharmaceutical Characterization and Monitoring Workflows
Manufacturing

Commercial Success In New Biopharmaceutical Innovation Era

21st May 2022
Manufacturing

Proteros and AstraZeneca Boost Collaboration Agreement

18th May 2022
SEQENS Makes Multi-Million-Dollar Investment in U.S. R&D Laboratory
Middle East and South Asia

SEQENS Makes Multi-Million-Dollar Investment in U.S. R&D Laboratory

22nd March 2022
Exscientia and Sanofi establish strategic research collaboration to develop AI-driven pipeline of precision-engineered medicines
Press Statements

Exscientia and Sanofi establish strategic research collaboration to develop AI-driven pipeline of precision-engineered medicines

17th January 2022
COVID-19 Impact On Changing Pharma Research And Development
News

COVID-19 Impact On Changing Pharma Research And Development

12th January 2022
immuno-oncology therapies
Drug Development

AbbVie, University of Chicago Extend Research Collaboration to Support Preclinical Oncology Research Through 2025

19th November 2021
Next Post

iMedrix Announces General Availability of KardioScreen, a CE certified, Connected ECG Device for Universal Use

Latest News

FDA Experts Recommend Changing COVID Jab Formulation In Fall
Manufacturing

FDA Experts Recommend Changing COVID Jab Formulation In Fall

30th June 2022
Novartis to acquire The Medicines Company for USD 9.7 bn
Manufacturing

Novartis To Slash 8,000 Jobs To Save $1 Billion By 2024

30th June 2022
How Lag In African COVID-19 Jabs Slowed Its Once Rapid Pace
Manufacturing

How Lag In African COVID-19 Jabs Slowed Its Once Rapid Pace

27th June 2022
Australia Creates A Novel Stem Cell Production Technique
Manufacturing

Australia Creates A Novel Stem Cell Production Technique

27th June 2022
Novartis to acquire The Medicines Company for USD 9.7 bn
Manufacturing

Novartis Promises $250M For Tropical Illnesses, Malaria

27th June 2022
Pharma Advancement

About Us

Pharma Advancement is a leading Pharma information centric website. On one side Pharmaadvancement.com has established itself as one of the most efficient and comprehensive source of Pharma information online, dedicated to providing decision makers in all the Pharma industry sectors with reliable, accurate and useful insights into happenings in the Pharma sector.

Qucik Links

  • Drug Development
  • Manufacturing
  • News
  • Events & Conferences
  • Newsletter Archive

Resources

  • Advertise with us
  • Contact Us
  • Download Mediapack

System

  • Search
  • Sitemap
  • RSS Feed

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

No Result
View All Result
  • Home
  • Drug Development
  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

Login to your account below

Forgotten Password?

Fill the forms bellow to register

All fields are required. Log In

Retrieve your password

Please enter your username or email address to reset your password.

Log In